The licence will allow manufacturers in India and China to develop generic versions of TAF for 112 countries.
With the new licence, generic manufacturers and other companies based anywhere in the world can develop, manufacture and sell low cost, paediatric versions of raltegravir in countries where 98 percent of children with HIV in the developing world live.
The Medicines Patent Pool Signs Licensing Agreement with AbbVie for HIV Paediatric Formulations of Lopinavir and Ritonavir
In May 2014 UNITAID, DNDi and MPP launched the PHTI to improve the lives of children living with HIV.
The Medicines Patent Pool (MPP) was created to increase access to quality, appropriate, affordable medicines for people living with HIV in developing countries.
The Medicines Patent Pool is a United Nations-backed organisation established in 2010 to improve access to appropriate, affordable HIV
medicines and technologies for people living with HIV in developing countries. Learn more.
Priority Antiretrovirals for the Medicines Patent Pool
The Patent Status Database for HIV Medicines
Recent Statements from the Executive Director
12 March 2015
24 February 2015
1 December 2014
26 November 2014
17 November 2014
The MPP by the numbers and more
Read the statement from the MPP’s Executive Director
UNITAID’s chair discusses HIV and the Medicines Patent Pool (Communauté de brevets) in Radio France Internationale interview on Dec. 1, 2014
Multilingual WordPress by ICanLocalize